

BC Cancer Protocol Summary for Adjuvant Treatment of Patients with Soft Tissue Sarcoma Using DOXOrubicin and Dacarbazine

Protocol Code SAAJADIC
Tumour Group Sarcoma
Contact Physician Dr. Christine Simmons

ELIGIBILITY/TESTS:

- Patient with soft tissue sarcoma
- Path not rhabdomyosarcoma, Ewings sarcoma or primitive neuroectodermal tumour
- Normal cardiac and hepatic function
- Pre-treatment: CBC and diff, liver functions tests, bilirubin, weight, ECOG-PS
- CXR every 3 months
- CT lungs before treatment and at completion
- Baseline EKG with treatment number 1 or 2.

PREMEDICATIONS:

Antiemetic protocol for highly emetogenic chemotherapy (see protocol SCNAUSEA)

TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
DOXOrubicin	60 mg/m ² *	IV push
dacarbazine	850 mg/m ²	IV in 500 to 1000 mL NS over 1 to 2 hours

* May escalate by 10 mg/m² if treatment day ANC greater than 2500 and no interval complications

- Repeat every three weeks for 6 cycles (MAXIMUM total DOXOrubicin dose of 360 mg/m²)

DOSE MODIFICATIONS:

1. Hematological

- Treatment day counts (modify both drugs)

ANC (x10 ⁹ /L)		Platelets (x10 ⁹ /L)	Dose (both drugs)
greater than or equal to 1.5	and	greater than or equal to 100	100%
1.0 to less than 1.5	or	70 to less than 100	80%
less than 1.0	or	less than 70	Delay for 1 week

2. Mucositis Grade 3 or 4 reduce DOXOrubicin by 20%.

3. **Neutropenic fever** with ANC less than $0.5 \times 10^9/L$ reduce both drugs by 20%.

Call Dr. Christine Simmons or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.